Go Pro
→ 4th of July Chaikin flash sale (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:BNTC

Benitec Biopharma Q2 2026 Earnings Report

Benitec Biopharma logo
$13.40 +0.18 (+1.39%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Benitec Biopharma EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Q2 2026
Date
2/12/2026
Time
Before Market Opens
Conference Call Date
Thursday, February 12, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Benitec Biopharma's Q2 2026 Press ReleasePress Release
(8-K)
Benitec Biopharma's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Benitec Biopharma Earnings Headlines

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages
July 3 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30875578
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294843/0/en/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-update.html
4th of July Chaikin flash sale
Marc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%.tc pixel
July 6 at 1:00 AM  |  Chaikin Analytics (Ad)
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the ...
April 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-1036071304
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282427/0/en/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-.html
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued ...
March 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-1035913741
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC) Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs.

Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications.

Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.

View Benitec Biopharma Profile
Earnings Tools